Correction: A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients

Trials

Correction

Yi Zhao¹  Wei Bai²  Xiaofeng Zeng²  Xiaomei Leng²  Fan Yang²  Huji Xu³  Yan Zhang⁴  Xiaofei Shi⁵  Wei Wei⁶  Hongbin Li⁷  Liyun Zhang⁸ 

[1] Department of Rheumatology and Allergy, Xuanwu Hospital, Capital Medical University, Beijing, China;Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, 100730, Beijing, China;Department of Rheumatology and Immunology, Changzheng Hospital, Naval Medical University, 200003, Shanghai, China;Department of Rheumatology and Immunology, Tangdu Hospital, Fourth Military Medical University (Air Force Medical University), Xi’an, Shaanxi, China;Department of Rheumatology and Immunology, The First Afliated Hospital and College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China;Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, China;Department of Rheumatology, The Afliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China;Department of Rheumatology, Third Hospital of Shanxi Medical University, Bethune Hospital Shanxi Academy of Medical Sciences, Taiyuan, Shanxi, China;

关键词: ;   

DOI  :  10.1186/s13063-023-07546-z

来源: Springer

【 授权许可】

CC BY   
© The Author(s) 2023